Cerebellar Non-invasive Stimulation in Ataxias

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03213106
Collaborator
(none)
30
1
2
36
0.8

Study Details

Study Description

Brief Summary

Cerebellar ataxias are a group of disorders caused by cerebellar affections, for which currently no specific treatment is available. Some limited studies verified the effects of cerebellar transcranial magnetic stimulation (TMS) on ataxic symptoms, with good results. So far it is not known which patients could benefit. Our hypothesis is that cerebellar TMS could improve ataxic symptoms in some patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial Magnetic Stimulation (TMS)
  • Device: Sham Stimulation
N/A

Detailed Description

Thirty patients with cerebellar ataxia will be included in our protocol. Ataxia might be due to several aetiologies, from degenerative to genetic and vascular diseases. Patients will be submitted to a neuronavigation protocol for the precise location of the dentate nucleus contralateral to the most symptomatic side. After that, participants will be randomly assigned to 5 active or 5 placebo sessions of 1Hz TMS over the located area. After the first 5 sessions and a period of at least 4 weeks washout, patients will cross over and receive other 5 sessions, active or sham. Clinical and video evaluations will be conducted before and after active and sham cluster of sessions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
5 sessions of active and sham rTMS separated by at least 4 weeks washout.5 sessions of active and sham rTMS separated by at least 4 weeks washout.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Cerebellar Transcranial Magnetic Stimulation in Cerebellar Ataxias
Actual Study Start Date :
Dec 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2017
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Transcranial Magnetic Stimulation (TMS) Stimulation

All patients will receive 5 sessions of active TMS stimulation.

Device: Transcranial Magnetic Stimulation (TMS)
Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.

Sham Comparator: Sham Stimulation

All patients will receive 5 sessions of active TMS stimulation

Device: Sham Stimulation
The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.

Outcome Measures

Primary Outcome Measures

  1. Percent Change From Baseline to Post Treatment on the Scale for the Assessment and Rating of Ataxia (SARA) [Day 1 (baseline), day 5 (after 5th TMS session, active or sham), day 33 (new baseline after TMS wash out) and day 38 (after 10th TMS session, active or sham)]

    Assess 8 items: gait, stance, sitting, speech, dysmetria, kinetic tremor, pro- and supinations of the hand, and the heel-shin slide. Each item is scored by the physician on a 4 to 8 numerical scale based upon the amount of dysfunction observed while performing the task. The maximum possible score for the total scale is 40. Lower scores of SARA represents better task performance.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • identification of cerebellar ataxia based on neurologic examination

  • no improvement after rehabilitation

  • symptoms onset of at least 6 months

Exclusion Criteria:
  • Younger than 18 months

  • Pregnant or breastfeeding women

  • Participation in other clinical trials

  • Epilepsy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital das Clínicas da Faculdade de Medicina da USP São Paulo SP Brazil 05403000

Sponsors and Collaborators

  • University of Sao Paulo General Hospital

Investigators

  • Principal Investigator: Rubens G Cury, MD PhD, University of Sao Paulo General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rubens Gisbert Cury, Dr Rubens Gisbert Cury, University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier:
NCT03213106
Other Study ID Numbers:
  • 1.310.275
First Posted:
Jul 11, 2017
Last Update Posted:
Jul 11, 2017
Last Verified:
Jul 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rubens Gisbert Cury, Dr Rubens Gisbert Cury, University of Sao Paulo General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 11, 2017